Coccidioidomycosis

Summary

Coccidioidomycosis (MONDO:0005706) is a disease and 15 clinical trials. Top therapeutic interventions include fluconazole, ibrexafungerp, and posaconazole. A subtype of primary systemic mycosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)
• Phenotypes (HPO): 76
• Clinical trials: 15

Clinical features

Signs & symptoms

Clinical features (HPO)

76 HPO clinical features (Orphanet curated; top 50 by frequency):

HPO ID	Term	Frequency
HP:0001945	Fever	Frequent (30-79%)
HP:0002090	Pneumonia	Frequent (30-79%)
HP:0002721	Immunodeficiency	Frequent (30-79%)
HP:0003237	Increased circulating IgG level	Frequent (30-79%)
HP:0003496	Increased circulating IgM level	Frequent (30-79%)
HP:0000707	Abnormality of the nervous system	Occasional (5-29%)
HP:0000987	Atypical scarring of skin	Occasional (5-29%)
HP:0000988	Skin rash	Occasional (5-29%)
HP:0000989	Pruritus	Occasional (5-29%)
HP:0001369	Arthritis	Occasional (5-29%)
HP:0001880	Eosinophilia	Occasional (5-29%)
HP:0002098	Respiratory distress	Occasional (5-29%)
HP:0002105	Hemoptysis	Occasional (5-29%)
HP:0002113	Pulmonary infiltrates	Occasional (5-29%)
HP:0002716	Lymphadenopathy	Occasional (5-29%)
HP:0002922	Increased CSF protein concentration	Occasional (5-29%)
HP:0003326	Myalgia	Occasional (5-29%)
HP:0011450	Unusual CNS infection	Occasional (5-29%)
HP:0011919	Pleural empyema	Occasional (5-29%)
HP:0011921	Exudative pleural effusion	Occasional (5-29%)
HP:0011972	Hypoglycorrhachia	Occasional (5-29%)
HP:0012219	Erythema nodosum	Occasional (5-29%)
HP:0012229	CSF pleocytosis	Occasional (5-29%)
HP:0012282	Morbilliform rash	Occasional (5-29%)
HP:0012378	Fatigue	Occasional (5-29%)
HP:0012490	Panniculitis	Occasional (5-29%)
HP:0012500	Verrucous papule	Occasional (5-29%)
HP:0012735	Cough	Occasional (5-29%)
HP:0025084	Folliculitis	Occasional (5-29%)
HP:0025615	Abscess	Occasional (5-29%)
HP:0030351	Urticarial plaque	Occasional (5-29%)
HP:0032177	Parenchymal consolidation	Occasional (5-29%)
HP:0032217	Indurated nodule	Occasional (5-29%)
HP:0032252	Granuloma	Occasional (5-29%)
HP:0100721	Mediastinal lymphadenopathy	Occasional (5-29%)
HP:0100749	Chest pain	Occasional (5-29%)
HP:0200034	Papule	Occasional (5-29%)
HP:0200035	Skin plaque	Occasional (5-29%)
HP:0200149	CSF lymphocytic pleiocytosis	Occasional (5-29%)
HP:0000014	Abnormality of the bladder	Very rare (<1-4%)
HP:0000077	Abnormality of the kidney	Very rare (<1-4%)
HP:0000083	Renal insufficiency	Very rare (<1-4%)
HP:0000119	Abnormality of the genitourinary system	Very rare (<1-4%)
HP:0000238	Hydrocephalus	Very rare (<1-4%)
HP:0000365	Hearing impairment	Very rare (<1-4%)
HP:0000479	Abnormal retinal morphology	Very rare (<1-4%)
HP:0000613	Photophobia	Very rare (<1-4%)
HP:0000622	Blurred vision	Very rare (<1-4%)
HP:0000751	Personality changes	Very rare (<1-4%)
HP:0000818	Abnormality of the endocrine system	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	coccidioidomycosis
Mondo ID	MONDO:0005706
EFO	EFO:0007211
MeSH	D003047
Orphanet	228123
DOID	DOID:13450
ICD-10-CM	B38
ICD-11	132287989
NCIT	C84642
SNOMED CT	23247008
UMLS	C0009186
MedGen	3137
GARD	0009525
MedDRA	10009825
Is cancer (heuristic)	no

Also known as: California disease · Coccidioides immitis caused disease or disorder · Coccidioides immitis disease or disorder · Coccidioides immitis infectious disease · Coccidioides infection · desert fever · desert rheumatism · San Joaquin valley fever · Valley fever

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › systemic mycosis › primary systemic mycosis › coccidioidomycosis

Related subtypes (5): adiaspiromycosis, allescheriosis, blastomycosis, paracoccidioidomycosis, histoplasmosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Posaconazole	Approved (phase 4)
Fluconazole	Phase 3 (in late-stage trials)
Ibrexafungerp	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Itraconazole, Sertraline.

Clinical trials & evidence

Clinical trials

Clinical trials: 15.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE3	3
PHASE2	2
PHASE4	1
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02663674	PHASE4	TERMINATED	Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
NCT00423267	PHASE3	COMPLETED	POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)
NCT00690092	PHASE3	COMPLETED	A Multi-center Study of Spherule-Derived Coccidioidin
NCT03059992	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
NCT00614666	PHASE1/PHASE2	TERMINATED	Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment
NCT02908334	PHASE2	WITHDRAWN	Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis
NCT04809649	PHASE2	WITHDRAWN	SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole
NCT04208321	PHASE1	COMPLETED	Safety and Pharmacokinetics of VT-1598
NCT02190266	Not specified	RECRUITING	Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis
NCT06913803	Not specified	ACTIVE_NOT_RECRUITING	To Find Effectiveness of Stretching Versus Soft Tissue Mobilization in Coccydynia in Postpartum Females
NCT00002325	Not specified	COMPLETED	A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common
NCT00796809	Not specified	COMPLETED	Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis
NCT03618992	Not specified	TERMINATED	Improving the Appearance of Skin and Hair in Patients Undergoing Valley Fever Treatment
NCT03908632	Not specified	COMPLETED	An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged > / = 14 Years Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC)
NCT06523998	Not specified	COMPLETED	A Study on Rare Dermatological Infections Conducted at Three Major Reference Hospitals in Costa Rica.

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FLUCONAZOLE	4	3
IBREXAFUNGERP	4	1
POSACONAZOLE	4	1
COCCIDIOIDIN	3	1
NIKKOMYCIN	1	1
VT-1598	1	1
CHEMBL4764856	0	1